Drug intelligence / Profile preview

LBS-009

Development stage: Preclinical
Lead developer: Belite Bio
Modality: Small Molecules
Administration: Oral

Overview

LBS-009 is a small molecule drug developed by Belite Bio, a subsidiary of Lin BioScience. It acts as an anti-RBP4 oral therapy targeting liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as type 2 diabetes (T2D). The drug works by competing with retinol for binding to retinol-binding protein 4 (RBP4), preventing RBP4 from interacting with transthyretin and leading to its removal from circulation via renal filtration. This mechanism is believed to have therapeutic potential for treating metabolic diseases associated with elevated RBP4 levels.

Targets

RBP4 (Retinol-binding protein 4)

Beyond the preview

Go deeper on LBS-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBS-009.

Explore the full profile